A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

NCT02514551 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Ramucirumab
DRUG: Paclitaxel

Sponsor

Eli Lilly and Company